My NCBISign In

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 795

    1.

    Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.

    Darb-Esfahani S, Loibl S, Müller BM, Roller M, Denkert C, Komor M, Schlüns K, Blohmer JU, Budczies J, Gerber B, Noske A, du Bois A, Weichert W, Jackisch C, Dietel M, Richter K, Kaufmann M, von Minckwitz G.

    Breast Cancer Res. 2009;11(5):R69. Epub .

    PMID:
    19758440
    [PubMed - indexed for MEDLINE]
    Free PMC Article

    Related citations

    2.

    Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy.

    von Minckwitz G, Müller BM, Loibl S, Budczies J, Hanusch C, Darb-Esfahani S, Hilfrich J, Weiss E, Huober J, Blohmer JU, du Bois A, Zahm DM, Khandan F, Hoffmann G, Gerber B, Eidtmann H, Fend F, Dietel M, Mehta K, Denkert C.

    J Clin Oncol. 2011 Jun 1;29(16):2150-7. Epub 2011 Apr 25.

    PMID:
    21519019
    [PubMed - indexed for MEDLINE]

    Related citations

    3.

    Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.

    Rody A, Karn T, Gätje R, Kourtis K, Minckwitz G, Loibl S, Munnes M, Ruckhäberle E, Holtrich U, Kaufmann M, Ahr A.

    Zentralbl Gynakol. 2006 Apr;128(2):76-81.

    PMID:
    16673249
    [PubMed - indexed for MEDLINE]

    Related citations

    4.

    Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer.

    Petit T, Wilt M, Velten M, Rodier JF, Fricker JP, Dufour P, Ghnassia JP.

    Breast Cancer Res Treat. 2010 Nov;124(2):387-91. Epub 2010 Sep 8.

    PMID:
    20824324
    [PubMed - indexed for MEDLINE]

    Related citations

    5.

    Common and discriminative clinicopathological features between breast cancers with pathological complete response or progressive disease in response to neoadjuvant chemotherapy.

    Osako T, Horii R, Matsuura M, Ogiya A, Domoto K, Miyagi Y, Takahashi S, Ito Y, Iwase T, Akiyama F.

    J Cancer Res Clin Oncol. 2010 Feb;136(2):233-41. Epub 2009 Aug 14.

    PMID:
    19685074
    [PubMed - indexed for MEDLINE]

    Related citations

    6.

    Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.

    Chang HR, Glaspy J, Allison MA, Kass FC, Elashoff R, Chung DU, Gornbein J.

    Cancer. 2010 Sep 15;116(18):4227-37.

    PMID:
    20549829
    [PubMed - indexed for MEDLINE]
    Free Article

    Related citations

    7.

    Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.

    von Minckwitz G, Sinn HP, Raab G, Loibl S, Blohmer JU, Eidtmann H, Hilfrich J, Merkle E, Jackisch C, Costa SD, Caputo A, Kaufmann M; German Breast Group.

    Breast Cancer Res. 2008;10(2):R30. Epub 2008 Apr 1.

    PMID:
    18380893
    [PubMed - indexed for MEDLINE]
    Free PMC Article

    Related citations

    8.

    HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.

    Yao L, Liu Y, Li Z, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.

    Ann Oncol. 2011 Jun;22(6):1326-31. Epub 2010 Dec 31.

    PMID:
    21196440
    [PubMed - indexed for MEDLINE]

    Related citations

    9.

    [Immunohistochemical phenotype of breast carcinomas predicts the effectiveness of primary systemic therapy].

    Kulka J, Tokés AM, Tóth AI, Szász AM, Farkas A, Borka K, Járay B, Székely E, Istók R, Lotz G, Madaras L, Korompay A, Harsányi L, László Z, Rusz Z, Molnár BA, Molnár IA, Kenessey I, Szentmártoni G, Székely B, Dank M.

    Magy Onkol. 2009 Dec;53(4):335-43. Hungarian.

    PMID:
    20071305
    [PubMed - indexed for MEDLINE]
    Free Article

    Related citations

    10.

    Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765).

    Noske A, Loibl S, Darb-Esfahani S, Roller M, Kronenwett R, Müller BM, Steffen J, von Toerne C, Wirtz R, Baumann I, Hoffmann G, Heinrich G, Grasshoff ST, Ulmer HU, Denkert C, von Minckwitz G.

    Breast Cancer Res Treat. 2011 Feb;126(1):109-17. Epub 2010 Dec 29.

    PMID:
    21190079
    [PubMed - indexed for MEDLINE]

    Related citations

    11.

    Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.

    Nikolényi A, Sükösd F, Kaizer L, Csörgo E, Vörös A, Uhercsák G, Ormándi K, Lázár G, Thurzó L, Brodowicz T, Kahán Z.

    Oncology. 2011;80(3-4):269-77. Epub 2011 Jul 7.

    PMID:
    21734419
    [PubMed - indexed for MEDLINE]

    Related citations

    12.

    The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.

    Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM.

    Clin Cancer Res. 2007 Apr 15;13(8):2329-34.

    PMID:
    17438091
    [PubMed - indexed for MEDLINE]
    Free Article

    Related citations

    13.

    HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma.

    Learn PA, Yeh IT, McNutt M, Chisholm GB, Pollock BH, Rousseau DL Jr, Sharkey FE, Cruz AB, Kahlenberg MS.

    Cancer. 2005 Jun 1;103(11):2252-60.

    PMID:
    15834928
    [PubMed - indexed for MEDLINE]
    Free Article

    Related citations

    14.

    Predictive biological markers for response of invasive breast cancer to anthracycline/cyclophosphamide-based primary (radio-)chemotherapy.

    Prisack HB, Karreman C, Modlich O, Audretsch W, Danae M, Rezai M, Bojar H.

    Anticancer Res. 2005 Nov-Dec;25(6C):4615-21.

    PMID:
    16334152
    [PubMed - indexed for MEDLINE]

    Related citations

    15.

    Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.

    Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G.

    Breast Cancer Res Treat. 2009 Jul;116(1):131-43. Epub 2008 Jul 31.

    PMID:
    18668363
    [PubMed - indexed for MEDLINE]

    Related citations

    16.

    Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.

    Sánchez-Muñoz A, García-Tapiador AM, Martínez-Ortega E, Dueñas-García R, Jaén-Morago A, Ortega-Granados AL, Fernández-Navarro M, de la Torre-Cabrera C, Dueñas B, Rueda AI, Morales F, Ramírez-Torosa C, Martín-Salvago MD, Sánchez-Rovira P.

    Clin Transl Oncol. 2008 Oct;10(10):646-53.

    PMID:
    18940745
    [PubMed - indexed for MEDLINE]

    Related citations

    17.

    Neoadjuvant chemotherapy of breast cancer: tumor markers as predictors of pathologic response, recurrence, and survival.

    Precht LM, Lowe KA, Atwood M, Beatty JD.

    Breast J. 2010 Jul-Aug;16(4):362-8. Epub 2010 Apr 28.

    PMID:
    20443786
    [PubMed - indexed for MEDLINE]

    Related citations

    18.

    Predictive value of serum anti-p53 antibodies, carcino-embryonic antigen, carbohydrate antigen 15-3, estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in taxane-based and anthracycline-based neoadjuvant chemotherapy in locally advanced breast cancer patients.

    Bao H, Yu D, Wang J, Qiu T, Yang J, Wang L.

    Anticancer Drugs. 2008 Mar;19(3):317-23.

    PMID:
    18510179
    [PubMed - indexed for MEDLINE]

    Related citations

    19.

    Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.

    Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munárriz B, Rodríguez CA, Crespo C, de Alava E, López García-Asenjo JA, Guitián MD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Seguí MA, Mayordomo JI, Antón A, Baena JM, Plazaola A, Modolell A, Pelegrí A, Mel JR, Aranda E, Adrover E, Alvarez JV, García Puche JL, Sánchez-Rovira P, Gonzalez S, López-Vega JM; GEICAM 9906 Study Investigators.

    J Natl Cancer Inst. 2008 Jun 4;100(11):805-14. Epub 2008 May 27.

    PMID:
    18505968
    [PubMed - indexed for MEDLINE]
    Free Article

    Related citations

    20.

    Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.

    Untch M, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Kühn T, du Bois A, Blohmer JU, Thomssen C, Dan Costa S, Jackisch C, Kaufmann M, Mehta K, von Minckwitz G.

    J Clin Oncol. 2010 Apr 20;28(12):2024-31. Epub 2010 Mar 22.

    PMID:
    20308670
    [PubMed - indexed for MEDLINE]

    Related citations

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Filter your results:

      Find related data

      Recent activity

      You are here: NCBI > Literature > PubMed
      Write to the Help Desk